PRX-115 Updated Nov 11
The next major catalyst is the Phase 2 RELEASE study (NCT07280156) topline results, expected in the second half of 2027. Positive data showing sustained uric acid reduction with infrequent dosing could significantly de-risk the program and support a path to registration. Negative or equivocal results would likely weigh heavily on the stock given PRX-115's importance as the lead pipeline asset. Interim data or updates at medical conferences in the interim could also move the stock.
- Phase 1 data showed that a single 36 mg dose of PRX-115 kept mean plasma uric acid levels below the 6.0 mg/dL therapeutic target for up to 12 weeks, suggesting potential for every-3-months or less frequent dosing versus every-2-weeks for Krystexxa, a major competitive advantage.
- PRX-115 plasma levels remained measurable for up to 85 days after a single dose, supporting the potential for infrequent maintenance dosing and improved patient convenience/compliance.
- Company management believes PRX-115 has best-in-class potential in uncontrolled gout based on its high specific activity, prolonged half-life, and reduced immunogenicity profile from the ProCellEx platform.
- PRX-115 faces entrenched competition from Krystexxa (pegloticase), the only FDA-approved uricase for uncontrolled gout, which was strengthened by FDA approval of methotrexate co-administration in 2022 to reduce infusion reactions and improve response rates.
- Phase 2 topline data is not expected until H2 2027, leaving a long period without a binary catalyst. The stock could drift or be subject to macro/sentiment swings in the interim.
- Uricase therapies carry inherent safety risks including infusion reactions and immunogenicity. PRX-115's PEGylated design aims to mitigate these, but Phase 2 data will be needed to confirm a differentiated safety profile.